CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Wilhelmsburg, Austria

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • First Observatory of Precocious Puberty.

    Phase

    N/A

    Span

    209 weeks

    Sponsor

    Hospices Civils de Lyon

    Ecully, Auvergne-Rhône-Alpes

    Recruiting

    Healthy Volunteers

  • Tolerability and Efficacy of INSTYLAN in Subjects With Moderate to Severe Hemorrhagic Cystitis

    This is a multicenter single-arm clinical study including male and female subjects with moderate to severe hemorrhagic cystitis caused by pelvic radiation therapy and/or chemotherapy as determined by the physician. A total of 30 subjects are anticipated and will be enrolled in 10 study sites in France. The patients will receive intravesical instillations with INSTYLAN weekly for 6 weeks. The objectives of the study are to assess the efficacy of intravesical instillations of INSTYLAN on the basis of hemorrhagic cystitis symptoms disappearance. The primary endpoint is the evaluation of pain using a verbal rating scale one week and four weeks after treatment versus Baseline.

    Phase

    N/A

    Span

    63 weeks

    Sponsor

    LIDDE Therapeutics

    Ecully

    Recruiting

  • A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

    Phase

    N/A

    Span

    251 weeks

    Sponsor

    Hoffmann-La Roche

    Ecully

    Recruiting

  • A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

    Phase

    3

    Span

    111 weeks

    Sponsor

    Hoffmann-La Roche

    Ecully

    Recruiting

  • Extension Study for the Port Delivery System With Ranibizumab (Portal)

    The Transscleral Photocoagulation sub-study (sub-study 1) will evaluate the effectiveness of using transscleral photocoagulation (TPC) with the Iridex laser system to mitigate vitreous hemorrhages secondary to the Port Delivery System with ranibizumab (PDS) implantation procedure in participants with neovascular age-related macular degeneration (nAMD). The sub-study will enroll about 55 participants. The Re-implantation sub-study (sub-study 2) will evaluate the safety of re-implantation with the updated PDS with ranibizumab . Up to 100 participants who previously participated in the main study in the United States will be enrolled and followed for a maximum of 72 weeks post-re-implantation in the substudy.

    Phase

    3

    Span

    576 weeks

    Sponsor

    Hoffmann-La Roche

    Ecully

    Recruiting

  • A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

    Phase

    3

    Span

    286 weeks

    Sponsor

    Hoffmann-La Roche

    Ecully

    Recruiting

1-6 of 6
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information